Biogen Due from unconsolidated joint business increased by 13.1% to $524.60M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.1%, from $464.00M to $524.60M. Over 5 years (FY 2020 to FY 2025), Due from unconsolidated joint business shows an upward trend with a 4.9% CAGR.
An increase reflects active collaboration and potential future cash inflows, while a decrease may signal the winding down of specific partnership activities.
This represents receivables or amounts owed to the company arising from collaborative arrangements or joint ventures tha...
Specific to companies with heavy reliance on R&D and commercialization partnerships, common in the pharmaceutical sector.
current_assets_due_from_unconsolidated_joint_business| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $412.30M | $431.40M | $435.90M | $464.00M | $524.60M |
| QoQ Change | — | +4.6% | +1.0% | +6.4% | +13.1% |
| YoY Change | — | +4.6% | +1.0% | +6.4% | +13.1% |